Celgene Corporation Contingent Value Rights
CELGZ
CELGZ was delisted on the 29th of November, 2019.
25 hedge funds and large institutions have $5.6M invested in Celgene Corporation Contingent Value Rights in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 9 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
4% less funds holding
Funds holding: 26 → 25 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
82% less capital invested
Capital invested by funds: $31.3M → $5.6M (-$25.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FA
FCG Advisors
Chatham,
New Jersey
|
+$1.18M |
| 2 |
DC
Davenport & Co
Richmond,
Virginia
|
+$168K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$102K |
| 4 |
First Manhattan
New York
|
+$78.6K |
| 5 |
U
UBS
Zurich,
Switzerland
|
+$56.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Ayer Capital Management
San Francisco,
California
|
-$11.2M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$5.72M |
| 3 |
O
OrbiMed
New York
|
-$2.9M |
| 4 |
AC
Amici Capital
New York
|
-$1M |
| 5 |
Millennium Management
New York
|
-$996K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DAM
26
Deltec Asset Management
New York
| – | -$404K | -50,300 | Closed |
|
|
JGC
27
J. Goldman & Co
New York
| – | -$322K | -40,000 | Closed |
|
|
FANJ
28
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$297K | -36,900 | Closed |
|
29
JP Morgan Chase
New York
| – | -$137K | -17,004 | Closed |
|
|
CCM
30
Consonance Capital Management
New York
| – | -$111K | -13,770 | Closed |
|
|
V
31
Veritable
Wilmington,
Delaware
| – | +$95 | +34 | New |
|
CELGZ Hedge Fund Activity: Q4 2013 in Review
25 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Celgene Corporation Contingent Value Rights (CELGZ) for Q4 2013, worth a combined $5.6M — down 82% from $31.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CELGZ and 8 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 6 added.
The largest buyer was FCG Advisors, adding an estimated $1.18M. The largest seller was Ayer Capital Management, exiting entirely with an estimated $11.2M sold.
- 25 institutional investors held Celgene Corporation Contingent Value Rights (CELGZ) as of Q4 2013, down from 26 in Q3 2013.
- Funds reported $5.6M of Celgene Corporation Contingent Value Rights stock for Q4 2013, down 82% quarter-over-quarter.
- 8 funds opened new Celgene Corporation Contingent Value Rights positions in Q4 2013 and 9 closed out, a net change of -1 holder.
- The largest Celgene Corporation Contingent Value Rights buyer in Q4 2013 was FCG Advisors, an estimated $1.18M added.
- The largest Celgene Corporation Contingent Value Rights seller in Q4 2013 was Ayer Capital Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q4 2013.